FDA delays approval of Bristol-Myers' belatacept

05/2/2010 | Reuters

Bristol-Myers Squibb has received a complete-response letter from the FDA for its kidney-transplant drug belatacept. The agency asked for additional data on the long-term effects of the treatment as well as the company's risk evaluation and mitigation plan for the product.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY